3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine

J Biomed Mater Res B Appl Biomater. 2018 May;106(4):1587-1594. doi: 10.1002/jbm.b.33965. Epub 2017 Aug 14.

Abstract

It is believed that an effective vaccine against leishmaniasis will require a T helper type 1 (TH 1) immune response. In this study, we investigated the adjuvanticity of the Toll-like receptor (TLR) 7/8 agonist 3M-052 in combination with the Leishmania donovani 36-kDa nucleoside hydrolase recombinant protein antigen (NH36). NH36 and 3M-052 were encapsulated in separate batches of poly(lactic-co-glycolic acid) (PLGA) microparticles (MPs). The loading efficiency for NH36 was 83% and for 3M-052 was above 95%. In vitro stimulation of bone marrow-derived dendritic cells, measured by IL-12 secretion, demonstrated that 3M-052 (free or MP-formulated) had a concentration-dependent immunostimulatory effect with an optimum concentration of 2 µg/mL. In immunogenicity studies in BALB/c mice, MP-formulated NH36 and 3M-052 elicited the highest serum titers of TH 1-associated IgG2a and IgG2b antibodies and the highest frequency of IFNγ-producing splenocytes. No dose dependency was observed among MP/NH36/3M-052 groups over a dose range of 4-60 µg 3M-052 per injection. The ability of MP-formulated NH36 and 3M-052 to elicit a TH 1-biased immune response indicates the potential for PLGA MP-formulated 3M-052 to be used as an adjuvant for leishmaniasis vaccines. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1587-1594, 2018.

Keywords: immune response; microparticle; poly(lactic-co-glycolic acid); vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Protozoan* / chemistry
  • Antigens, Protozoan* / pharmacology
  • Dose-Response Relationship, Immunologic
  • Heterocyclic Compounds, 3-Ring* / chemistry
  • Heterocyclic Compounds, 3-Ring* / pharmacology
  • Immunogenicity, Vaccine
  • Leishmania donovani / immunology*
  • Leishmaniasis Vaccines* / chemistry
  • Leishmaniasis Vaccines* / pharmacology
  • Leishmaniasis, Visceral* / immunology
  • Leishmaniasis, Visceral* / pathology
  • Leishmaniasis, Visceral* / prevention & control
  • Mice
  • Mice, Inbred BALB C
  • Molybdoferredoxin
  • Polylactic Acid-Polyglycolic Acid Copolymer* / chemistry
  • Polylactic Acid-Polyglycolic Acid Copolymer* / pharmacology
  • Protozoan Proteins* / chemistry
  • Protozoan Proteins* / pharmacology
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / pharmacology
  • Stearic Acids* / chemistry
  • Stearic Acids* / pharmacology

Substances

  • Antigens, Protozoan
  • Heterocyclic Compounds, 3-Ring
  • Leishmaniasis Vaccines
  • Molybdoferredoxin
  • Protozoan Proteins
  • Recombinant Proteins
  • Stearic Acids
  • LACK antigen, Leishmania
  • MEDI9197
  • Polylactic Acid-Polyglycolic Acid Copolymer